Skip to Content

Drug Interactions between aminolevulinic acid and Okebo

This report displays the potential drug interactions for the following 2 drugs:

  • aminolevulinic acid
  • Okebo (doxycycline)

Edit list (add/remove drugs)

Interactions between your drugs


doxycycline aminolevulinic acid

Applies to: Okebo (doxycycline) and aminolevulinic acid

Aminolevulinic acid sensitizes your skin to bright lights, and combining it with other medications that can also have this effect (i.E., photosensitivity) such as doxycycline may increase the risk of a severe sunburn. In general, it is recommended that other potentially photosensitizing medications be avoided for 24 hours before and after taking aminolevulinic acid. There have also been suggestions to avoid these medications for up to 2 weeks afterwards, although it may not be feasible to interrupt some treatments for that long, especially if they are medically necessary. Check with your doctor to see if you should temporarily withhold any of your medications before and after taking aminolevulinic acid. Following treatment, you should avoid exposure of the eyes and skin to sunlight or bright indoor lights for 48 hours. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Drug and food interactions

No interactions were found. This does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.